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Background: Transduction of human mesenchymal stem cells (MSCs) with type 5 adenoviruses (Ad5) is limited in
the efficacy because of the poor expression level of the coxsackie adenovirus receptor (CAR) molecules. We
examined a possible improvement of Ad-mediated gene transfer in MSCs by substituting the fiber region of type 5
Ad with that of type 35 Ad.
Methods: Expression levels of CAR and CD46 molecules, which are the major receptors for type 5 and type 35 Ad,
respectively, were assayed with flow cytometry. We constructed vectors expressing the green fluorescent protein
gene with Ad5 or modified Ad5 bearing the type 35 fiber region (AdF35), and examined the infectivity to MSCs
with flow cytometry. We investigated anti-tumor effects of MSCs transduced with interleukin (IL)-28A gene on human
lung carcinoma cells with a colorimetric assay. Expression of IL-28A receptors was tested with the polymerase chain
reaction. A promoter activity of transcriptional regulatory regions in MSCs was determined with a luciferase assay
and a tumor growth-promoting ability of MSCs was tested with co-injection of human tumor cells in nude mice.
Results: MSCs expressed CD46 but scarcely CAR molecules, and subsequently were transduced with AdF35 but not
with Ad5. Growth of MSCs transduced with the IL-28A gene remained the same as that of untransduced cells since
MSCs were negative for the IL-28A receptors. The IL-28A-transduced MSCs however suppressed growth of lung
carcinoma cells co-cultured, whereas MSCs transduced with AdF35 expressing the β-galactosidase gene did not.
A regulatory region of the cyclooygenase-2 gene possessed transcriptional activities greater than other tumor
promoters but less than the cytomegalovirus promoter, and MSCs themselves did not support tumor growth
in vivo.
Conclusions: AdF35 is a suitable vector to transduce MSCs that are resistant to Ad5-mediated gene transfer.
MSCs infected with AdF35 that activate an exogenous gene by the cytomegalovirus promoter can be a vehicle
to deliver the gene product to targeted cells.
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Bone marrow-derived mesenchymal stem cells (MSCs)
have ability to differentiate into many kinds of tissues
under a certain condition [1,2]. The pluripotency as pro-
genitor cells indicates a potential clinical utility in mul-
tiple areas including tissue engineering. Furthermore,
MSCs tend to migrate into inflammatory regions, dam-
aged areas and tumors [3,4], which increases applica-
tions of MSCs as a tool to deliver an agent to target
tissues and cells. Gene and cell therapy can be one of
the directions to use MSCs as a cellular vehicle that dis-
tributes a therapeutic gene product into target cells and
tumors. Administration of transduced MSCs in the vicin-
ity of tumors can transport the gene product into the
microenvironment as well.
Adenoviruses (Ad)-mediated transduction is one of
the efficient methods to transfer an exogenous gene into
human cells. The transduction efficacy with Ad vectors
is however influenced by expression levels of the recep-
tor molecules on target cells [5]. Attachment of type 5
Ad (Ad5), commonly used in a gene transfer system, to
cells is mediated primarily by the binding of Ad fibers,
which include the shaft and the knob regions, to the cel-
lular receptor, the coxsackie adenovirus receptor (CAR)
molecules, and secondly by the interaction between Ad
penton bases and integrin molecules [6]. Expression
levels on CAR molecules are dependent on respective
cells and are often down-regulated in human tumors,
which resulted in poor transduction efficacy in CAR-low
cells [7]. On the other hand, subgroup B Ad such as type
35 use CD46 molecules as one of the major receptors
and infect cells in a CAR-independent manner [8]. CD46
is expressed in a variety of human cells and the expression
levels were not down-regulated in tumors. Recombinant
Ad5 of which the fiber region is replaced with that of type
35 Ad (AdF35) can therefore infect cells in a similar man-
ner as type 35 Ad through the type 35-derived fibers,
which may widen a scope of target cells that are restricted
by non-ubiquitous CAR distributions.
A new class of interferon (IFN), type III IFNs compris-
ing of IFN-λ1, -λ2 and -λ3 which are also known as
interleukin-29 (IL-29), IL-28A and IL-28B, respectively,
has a similar biological functions as type I IFNs such as
IFN-α and IFN-β [9,10]. The receptor complex of type III
IFNs is composed of the IL-10 receptor beta (IL-10Rβ)
and a novel IL-28 receptor alpha (IL-28Rα). In contrast to
ubiquitous expression of IL-10Rβ, IL-28Rα expression is
restricted to be tissue-specific, which subsequently con-
fines the biological activities in IL-28Rα positive cells. The
type III IFNs produce an anti-proliferative activity and in-
duce apoptosis to a certain type of the receptor positive
tumors including lung carcinoma [11] and esophageal car-
cinoma [12]. Moreover, several studies demonstrated that
type III IFNs expressed in tumors achieved anti-tumoreffects in vivo and some of the effects were mediated by
non-immune mechanisms including anti-angiogenesis
and by immunological responses such as activation of
natural killer cells and dendritic cells [13-17].
In this study, we examined infectivity of Ad5 and
AdF35 to human MSCs and investigated a possible use
of MSCs as a vehicle to deliver gene products to tumors.
We transduced MSCs with the IL-28A gene using a
replication-incompetent AdF35 vector and tested whether
the transduced MSCs produced cytotoxicty to tumor cells
co-cultured. We also examined promoter activities in
MSCs regarding transcriptional regulatory regions of the
genes which are preferentially activated in human tumors.
Methods
Cells and mice
Human embryonic kidney HEK293 cells, human esopha-
geal carcinoma YES-2 and TE-11 cells, human lung car-
cinoma OBA-LK1 cells, human immortalized fibroblasts
OUMS-24 [18] and HFF cells [19], were cultured with
RPMI1640 cells supplemented with 10% fetal bovine
serum. MSCs derived from human bone marrow (PT-2501)
(Cambrex, Rutherford, NJ, USA) were maintained with
Mesenchymal Stem Cell Basal Medium (MSCBM; Cam-
brex). BALB/c nu/nu mice were purchased from Japan
SLC (Hamamatsu, Japan).
Flow cytometry for receptor expression
Cells were stained with fluorescein isothiocyanate (FITC)-
conjugated anti-CD46 antibody (Ab) (BD Bioscience, San
Jose, CA) or FITC-conjugated isotype-matched control
Ab (BD Biosciences) as a control, or were reacted with
anti-CAR (Upstate, Lake Placid, NY, USA), anti-CD51
(Chemicon, Temecula, CA, USA), anti-αvβ3 (Chemicon)
or anti-αvβ5 Ab (Abcam, Cambridge, MA, USA) followed
by FITC-conjugated goat anti-mouse IgG Ab (Kirkegaard
& Perry, Gaithersburg, MD, USA). They were then ana-
lyzed for the fluorescence intensity with FACSCalibur (BD
Bioscience) and CellQuest software (BD Bioscience).
Construction of Ad vector
The green fluorescent protein (GFP), the β-galactosidase
(LacZ), the human IL-28A genes were cloned into pShut-
tle 2 (Takara Bio, Tokyo, Japan) and then ligated with
Adeno-X vector (Takara Bio) of which the fiber region was
replaced with that of type 35 Ad. The fiber modified Ad
DNA was produced by inserting the Eco RI fragment
containing the type 35 Ad fiber region (Avior thera-
peutics, Seattle, WA) (AY271307 at 30827–33609) into
the corresponding site of Adeno-X vector DNA. The fiber
modified Ad expressing the above genes, AdF35-GFP,
AdF35-LacZ, and AdF35-IL-28A, and type 5 Ad bear-
ing the GFP gene (Ad5-GFP) were produced by transfecting
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Adeno-X virus purification kit (BD Biosciences).
Infectivity of Ad
Cells were infected with Ad5-GFP or AdF35-GFP at
multiplicity of infection (MOI) of 3 or 30 for 30 min and
were washed to remove Ad. Infected cells were cultured
for 2 days and then analyzed for percentages of GFP-
positive cells with FACSCalibur and CellQuest software.
Cells of which fluorescence was greater than the brightest
5% of uninfected cells were judged as positively stained.
Reverse transcription-polymerase chain reaction (RT-PCR)
First-strand cDNA was synthesized with Superscript III
reverse transcriptase (Invitrogen, Carlsbad, CA) and
amplification of equal amounts of the cDNA was per-
formed with the following primers and conditions: for
the IL-28Rα gene, 5’-GGGAACCAAGGAGCTGCTAT
G-3’ (sense) and 5’-TGGCACTGAGGCAGTGGTGT
T-3’ (anti-sense), and 10 sec at 94°C for denature/20 sec
at 58°C for annealing/28 cycles; for the IL-10Rβ gene,
5’-TATTGGACCCCCTGGAAT-3’ (sense) and 5’-GTA
AACGCACCACAGCAA-3’ (anti-sense), and 10 sec at
94°C/20 sec at 50°C/28 cycles; for the glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) gene, 5’-ACCAC
AGTCCATGCCATCAC-3’ (sense) and 5’-TCCACCAC
CCTGTTGCTGTA-3’ (anti-sense), and 15 sec at 94°C/
15 sec at 60°C/25 cycles.
Cytotoxic test and enzyme-linked immunosorbent assay
(ELISA)
OBA-LK1 cells were cultured in 96-well plates with
MSCs uninfected or infected with AdF35-IL-28A or
AdF35-LacZ (MOI = 100), at a ratio of 10: 1 or 10: 3.
Cell viabilities after 4-days culture were assayed with a
WST kit (Dojindo, Kumamoto, Japan) which detected
the amounts of formazan produced from the WST-8 re-
agent with the absorbance at 450 nm (WST assay).
OBA-LK1 cells were also labeled with PKH 26 dye ac-
cording to the manufacturer’s protocol (Sigma-Aldrich,
St Louis, MO, USA) and cultured with MSCs, unin-
fected or infected with AdF35-IL-28A or AdF35-LacZ
(MOI = 100), at a ratio of 10: 1 or 10: 3 for 4 days. They
were then stained with Hoechst 33342 dye (Molecular
Probes, Eugene, OR, USA) and numbers of PKH 26
positive and Hoechst 33342 positive cells were counted
with confocal microscope (Olympus, Tokyo, Japan). The
amounts of secreted IFN-28A were determined by an
ELISA kit (R&D Systems, Minneapolis, MN).
Dual luciferase assay
Genomic fragments containing a transcriptional regula-
tory region of the midkine (0.6 kb, GenBank: D10604)
[20], the survivin (0.5 kb, GenBank: U75285) [21], or thecyclooxygenase-2 (0.3 kb, GenBank: U04636) gene [22]
were cloned into pGL-2 basic vector (Promega, Madison,
WI, USA) that contained the firefly luciferase gene. Plas-
mid DNA containing the respective genomic fragments,
pGL-control vector (Promega) harboring the SV40 T anti-
gen promoter-linked firefly luciferase gene, pGL-2 basic
vector containing the cytomegalovirus (CMV) promoter
or pGL-basic vector without any transcriptional regulatory
regions (Promega), and a control vector, the renilla lucifer-
ase gene fused with the herpes simplex virus-thymidine
kinase gene promoter (pRL-TK, Promega), at a molar ratio
of 10: 1, was transfected into MSCs with a lipofectin re-
agent (Life Technologies, Gaithersburg). Cell lysate on day
2 was assayed for the luciferase activity with the dual lucif-
erase reporter assay (Promega). The firefly luciferase activ-
ity was standardized by the amounts of luminescence
produced by renilla luciferase and the relative activity
was expressed as a percentage of the SV40 T antigen
promoter-mediated activity.
Animal study
YES-2 cells (1 × 106) and MSCs or OUMS-24 cells at a
ratio 5: 1 or 2: 1 (2 × 105 or 5 × 105) were inoculated
subcutaneously into BALB/c nu/nu mice (6-week-old
females). Tumor volume was calculated according to the
formula (1/2 × length x width2).
Statistical analysis
Statistical analysis was conducted with the one-way ana-
lysis of variance (ANOVA).
Results
Expression of Ad receptors on MSCs
We examined expression levels of CAR and CD46 mole-
cules, the major Ad receptors of type 5 and type 35, respect-
ively, on HEK293 cells and MSCs (Figure 1A). HEK293
cells, often used for Ad productions, expressed both recep-
tors, whereas MSCs scarcely expressed CAR but were posi-
tive for CD46 expression. We also tested integrin molecules
which were subsidiary receptors for type 5 Ad (Figure 1B).
Both HEK293 cells and MSCs expressed CD51 that corre-
sponded to integrin αv chain, αvβ3 and αvβ5 molecules. We
calculated relative expression levels of these receptor mole-
cules on MSCs in comparison with HEK293 cells and
showed that MSCs expressed poorly CAR, moderately
CD46 and well integrin molecules (Figure 2).
Infectivity of Ad5 and AdF35 to MSCs
We investigated efficacy of Ad5- and AdF35-mediated
transduction with respective Ad bearing the GFP gene
(Figure 3A). HEK293 cells became GFP positive after
transduction with either Ad5-GFP or AdF35-GFP, but
MSCs expressed GFP only when transduced with AdF35-









Figure 1 Expression of Ad receptors on HEK293 cells and MSCs. Representative flow cytometry profiles of HEK293 cells and MSCs that were
stained with (A) anti-CAR, anti-CD46, (B) anti-CD51, anti-integrin αvβ3 or anti-integrin αvβ5 Ab. Shaded areas and bold lines show unstained and
stained cells, respectively.
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http://www.biomedcentral.com/1471-2407/14/713cells were not different when they were transduced either
with Ad5-GFP or AdF35-GFP (Figure 4). In contrast, GFP
positive MSCs cells were undetected with Ad5-mediated
transduction and the positive percentages after transduc-
tion with AdF35-GFP were lower than those of HEK293
cells. The differential GFP positive rates were attributableto viral infectivity to the cells since both Ad5-GFP and
AdF35-GFP used the same CMV promoter.
Anti-tumor effects of MSCs infected with AdF35-IL-28A
IL-28A produced cytotoxic effects on cells expressing the

































Figure 2 Compared expression levels of Ad receptors between
MSCs and HEK293 cells. Mean fluorescence intensity in staining
profiles was expressed as an arbitrary FL1 unit and the relative ratios,
MSCs/HEK293 cells, are shown as a percentage. SE bars are also













Figure 3 Infectivity of Ad to MSCs. (A) Schematic structures of Ad5-GFP a
GFP gene. (B) Representative flow cytometry profiles of HEK293 cells and MSCs
stained population, and shaded areas and bold lines show uninfected and infe
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blasts, OUMS-24 and HFF cells, and esophageal carcin-
oma TE-11 cells as a reference of normal cells and as a
positive control for the IL-28A receptor complex, respect-
ively (Figure 5A) [12]. MSCs and the fibroblasts expressed
IL-10Rβ but not IL-28Rα, demonstrating that MSCs were
insensitive to IL-28A. In contrast, the esophageal carcin-
oma cells were positive for both molecules [12].
We then examined possible cytotoxicity of IL-28A re-
leased from MSCs in a co-culture experiment. Lung car-
cinoma OBA-LK1 cells were positive for the IL-28A
receptor complex and the growth was suppressed by re-
combinant IL-28A [11]. We infected MSCs with AdF35-
IL-28A or AdF35-LacZ as a control and detected IL-28A
released from MSCs with ELISA at 363 ± 4.61 pg/ml/day
per 103 MSCs. IL-28A-sensitive OBA-LK1 cells were
mixed with the MSCs and the viable cell numbers were
estimated with the WST assay (Figure 5B). Viability of
MSCs that were either uninfected or infected with Ad-
IL-28A or Ad-LacZ was not statistically different, show-
ing that expression of IL-28A did not induce growth
suppression in MSCs. In contrast, absorbance of a mixed
population consisting of OBA-LK1 cells and AdF35-IL-
28A-infected MSCs was lower than that of a mixture of
OBA-LK1 cells and either uninfected MSCs or AdF35-







nd AdF35-GFP. The E1 region was replaced with the CMV promoter-linked
that were infected with Ad5-GFP or AdF35-GFP. M1 indicates positively
cted cells, respectively.









































Figure 5 Growth inhibition of MSCs transduced with AdF35-IL-28.
(A) Expression of IL-28 receptor complexes in human fibroblasts and
MSCs. RT-PCR showed IL-28Rα and IL-10β gene products. TE-11 cells
were used as a positive control for the gene expression and GAPDH
as a loading control. (B) MSCs (100 or 300/well), uninfected or infected
with AdF35-IL-28A or AdF35-LacZ (MOI = 100), were cultured alone or
with OBA-LK1 cells (1,000/well) for 4 days. Viability of each group was
detected with the WST-8 reagent and expressed as absorbance at 450 nm.
SE bars are also shown (n= 3). *P < 0.05 and #P < 0.01, comparing MSCs























Ad5 AdF35 Ad5 AdF35
Figure 4 Infectivity of Ad5 and AdF35 to MSCs. MSCs or HEK293
cells were infected with Ad5-GFP or AdF35-GFP (MOI = 3 or 30) and
cell populations greater than the brightest 5% of uninfected cells
were judged as GFP-positive. SE bars are also shown (n = 3).
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even lower than that of OBA-LK1 cells alone, indicating
that IL-28A released from MSCs inhibited growth of
OBA-LK1 cells.
We confirmed growth inhibitory activities of MSCs trans-
duced with AdF35-IL-28A in a different assay (Table 1).
OBA-LK1 cells were labeled with PKH 26 and cultured with
MSCs for 4 days. We then stained all the cells with Hoechst
33342 and calculated numbers of PKH 28 positive cells
among Hoechst 33342 positive cells. Percentages of PKH 28
positive OBA-LK1 cells were about 80% because the PKH
28 labeling was not complete under the experimental condi-
tion. OBA-LK1 cells cultured with untransduced MSCs fur-
ther decreased the PKH 28 positive ratio since PKH 26
negative MSCs were also counted. Percentages of PKH 26
positive cells in cell mixtures were not different between
co-culture with uninfected MSCs and that with AdF35-
LacZ-infected MSCs irrespective of a ratio of the mix-
tures. The percentages however significantly lower in
co-culture with AdF35-IL-28A-infected MSCs com-
pared with cell mixture with uninfected MSCs or AdF35-
LacZ infected MSCs. These data demonstrated that
MSCs-derived IL-28A inhibited growth of OBA-LK1
cells.
Transcriptional regulation and growth assistance in MSCs
We investigated whether a putative tumor promoter could
activate the luciferase gene in non-tumorous MSCs. We
therefore examined transcriptional regions of the midkine,
the survivin and the COX-2 genes for the promoteractivity in MSCs with the SV40 T antigen promoter region
as a reference (Table 2). These regions are often used
for activation of a transgene in a tumor-specific man-
ner. A regulatory region of the COX-2 gene activated
the luciferase gene greater than that of the midkine or
the survivin gene. A transcriptional activity of the COX
region was greater than that of the SV40 T antigen pro-
moter, but much less than that of the CMV promoter
which is commonly used for transgene activations in many
cells.
We also examined a possible tumor growth-promoting
activity of MSCs with animal experiments (Figure 6).
We inoculated YES-2 esophageal carcinoma cells into
nude mice without or with MSCs or fibroblasts OUMS-
24. Tumor growth of mixed populations, irrespective of






PKH 26 positive cells
(Percentage ± SE)1
(+) (−) 80.2 ± 2.0
(+) None 10 : 1 57.4 ± 4.2*
(+) AdF35-LacZ 10 : 1 65.6 ± 4.1*
(+) AdF35-IL28A 10 : 1 47.6 ± 2.7*
(+) None 10 : 3 67.0 ± 4.4#
(+) AdF35-LacZ 10 : 3 56.1 ± 2.0#
(+) AdF35-IL-28A 10 : 3 26.4 ± 1.4#
OBA-LK1 cells (3.3 ×104) stained with PKH 26 were cultured with MSCs at a
ratio indicated, and all the cells were then stained with Hoechst 33342 on day
4. 1Percentages of PKH 26 positive cells among Hoechst 33342 positive cells
and SEs are also shown (n = 3).
*P < 0.05 and #P < 0.01, comparing between cells mixed with AdF35-IL-28A-
infected MSCs and cells mixed with uninfected MSCs or
AdF35-LacZ-infected MSCs.
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YES-2 cells alone, demonstrating that MSCs, like fibro-
blasts, did not support tumor growth of YES-2 esopha-
geal carcinoma cells co-injected.
Discussion
We showed that MSCs were resistant to Ad5-mediated
gene transfer but were transduced with fiber-modified
AdF35 vectors. The transduction preference was linked
with the Ad receptor expression on MSCs, which were
negative for CAR but positive for CD46 molecules.
Comparison of receptor expressions between HEK293
cells and MSCs further showed that CD46 expression
levels on MSCs were not as great as those on HEK293
cells, which resulted in lower transduction efficacy of
AdF35 to MSCs than to HEK293 cells. Interestingly, ex-






(−) 16.8 ± 8.9
SV40 T antigen 100.0 ± 11.5*
Midkine 66.8 ± 27.6*
Survivin 47.5 ± 14.7*
COX-2 368.2 ± 182.8*
CMV 6323.4 ± 2067.3*
1Relative luciferase activity was calculated based on the SV40 T antigen
promoter-mediated activity as 100%. SEs are shown (n = 3).
*P < 0.05, comparing between the COX-2 region and either the SV40 T antigen,
the survivin regulatory region, the midkine regulatory region or the
CMV promoter.greater on MSCs than on HEK293 cells. Nevertheless,
transduction of MSCs with Ad5 was not detected, indicat-
ing that the integrin molecules did not play a role as an
auxiliary receptor in MSCs although the integrin mole-
cules were demonstrated to be the major receptor of Ad5
in CAR-deficient cells [23]. In addition, the integrin mole-
cules were shown to enhance AdF35-mediated gene trans-
duction [24], but the present study suggested that elevated
expression levels of integrin molecules on MSCs cells
could not restore transduction efficacy of AdF35 to
MSCs to the same level as to HEK293 cells. Many fac-
tors seem to be involved in mechanisms underlying Ad in-
fectivity and the mechanisms can be different among cell
types tested. They may include a possible threshold level
of the receptor expression necessary for Ad infection and
a presumable reciprocal interaction among the receptor
molecules. CD46 is not a sole receptor for AdF35 and the
expression levels were relatively low in freshly isolated
MSCs [25]. Nevertheless, the MSCs from adult donors
were infected with AdF35 [25], and we presume that Ad
vectors bearing the type 35 fiber is currently one of the ef-
ficient vectors for gene transfer into MSCs.
Usage of gene modified MSCs has several advantages
over direct Ad administrations in the anti-tumor activity.
Transduced MSCs, injected intratumorally, tend to localize
at the tumor sites in contrast to Ad which are subjected to
a rapid washout from the injection sites [26]. Propensity of
MSCs to migrate into tumors is thus favorable for MSCs-
mediated anti-tumor effects [27] although the property
was dependent on an experimental system [28]. Adminis-
tration of MSCs into a tumor site also needs careful con-
sideration since MSCs can promote the tumor growth due
to the ability to constitute and maintain the microenviron-
ments around tumors. We thereby examined the possible
growth-enhancing activity in vivo and showed that MSCs
did not support tumor growth of esophageal carcinoma
cells co-injected. MSCs were not able to enhance tumor
growth in nude mice but the possibility of tumor promot-
ing actions needs to be studied in different experimental
models. On the other hand, the present study showed that
untransduced MSCs did not achieve any anti-tumor effects
by themselves. The growth suppressing activity of trans-
duced MSCs was thus attributable to IL-28A since the
suppression was dependent on cell numbers of IL-28-
transduced but not on β-galactosidase-transduced MSCs.
A property of expressed transgene products is also crucial
for therapeutic efficacy of MSCs-mediated gene delivery.
For example, IL-28A not only induces tumor cell death
through apoptosis but activates inmate and acquired im-
munity through augmented natural killer activities and
facilitated antigen presentation [12,14-17]. Moreover,
IL-28A in vivo influences and modulates tumor micro-
environments such as inhibition of angiogenesis, which























Figure 6 MSCs did not influence growth of co-injected tumors. YES-2 cells and MSCs or OUMS-24 cells were inoculated subcutaneously into
BALB/c nu/nu mice at the ratios indicated. Average tumor volumes and SE bars are shown (n = 6).
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fects produced by MSCs-mediated delivery of replication-
competent Ad into tumors [28,29] and a clinical research
revealed benefits of such autologous MSCs in neuroblast-
oma patients [30]. Tumor cells were initially used for cell-
mediated delivery of replication-competent Ad [31] since
tumor cells well supported Ad replication compared with
non-transformed cells. MSCs may not be effective in the
light of production of progenitor Ad because of the low
proliferation rate. We examined the promoter activity of
transcriptional regulatory regions which activated the Ad
E1A gene and subsequently enabled Ad replication-
competent within tumors [32-34]. The COX-2 region gave
greater activities than the midkine or the survivin region.
Expression levels of midkine and survivin in adult tissues
are often associated with proliferation rates of cells [35]
and relatively low promoter activities of these regions
could reflect the low growth rates of MSCs. Instead,
COX-2 expression can be liked with inflammatory re-
sponses [36,37]. Elevated promoter activity of the COX-2
region in MSCs may be related to MSCs’ propensity to
migrate toward inflammatory sites. Nevertheless, a pro-
moter activity of the COX-2 region was much lower than
that of the CMV promoter which is commonly used to ac-
tivate a transgene in replication-incompetent Ad. These
data suggest that MSCs are a suitable cell-mediate vehicle
for CMV promoter-driven replication-incompetent Ad ra-
ther than for replication-competent Ad in which the E1A
is activated by an exogenous transcriptional regulatory
region.Conclusions
We demonstrated anti-tumor effects of MSCs-mediated
delivery of IL-28A to lung carcinoma cells in the vicinity.
A local administration of gene-modified MSCs can de-
liver the gene product to targets and is one of the cell
therapies for cancer. AdF35 is a better vector than con-
ventional type 5 Ad in transducing MSCs because of its
enhanced infectivity. Immune responses against gene-
modified MSCs are less significant as long as MSCs are
autologously isolated. Nevertheless, when MSCs are in-
fected with replication-competent Ad, cell-mediated im-
munity against viral gene-loaded MSCs will be generated.
Further investigations are required for the cell-mediated
immunity in the light of Ad-loaded MSCs and for the
strategy to evade host immunity such as use of immuno-
suppressive agents.Abbreviations
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